GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SynAct Pharma AB (OSTO:SYNACT) » Definitions » Equity-to-Asset

SynAct Pharma AB (OSTO:SYNACT) Equity-to-Asset : 0.77 (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is SynAct Pharma AB Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. SynAct Pharma AB's Total Stockholders Equity for the quarter that ended in Dec. 2023 was kr176.19 Mil. SynAct Pharma AB's Total Assets for the quarter that ended in Dec. 2023 was kr228.02 Mil.

The historical rank and industry rank for SynAct Pharma AB's Equity-to-Asset or its related term are showing as below:

OSTO:SYNACT' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.47   Med: 0.75   Max: 0.89
Current: 0.77

During the past 8 years, the highest Equity to Asset Ratio of SynAct Pharma AB was 0.89. The lowest was 0.47. And the median was 0.75.

OSTO:SYNACT's Equity-to-Asset is ranked better than
62.78% of 1561 companies
in the Biotechnology industry
Industry Median: 0.67 vs OSTO:SYNACT: 0.77

SynAct Pharma AB Equity-to-Asset Historical Data

The historical data trend for SynAct Pharma AB's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SynAct Pharma AB Equity-to-Asset Chart

SynAct Pharma AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial 0.47 0.74 0.54 0.89 0.77

SynAct Pharma AB Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.89 0.84 0.81 0.76 0.77

Competitive Comparison of SynAct Pharma AB's Equity-to-Asset

For the Biotechnology subindustry, SynAct Pharma AB's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SynAct Pharma AB's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SynAct Pharma AB's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where SynAct Pharma AB's Equity-to-Asset falls into.



SynAct Pharma AB Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

SynAct Pharma AB's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=176.186/228.018
=

SynAct Pharma AB's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=176.186/228.018
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SynAct Pharma AB  (OSTO:SYNACT) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


SynAct Pharma AB Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of SynAct Pharma AB's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


SynAct Pharma AB (OSTO:SYNACT) Business Description

Traded in Other Exchanges
Address
Sheelevagen 2, Lund, SWE, 223 81
SynAct Pharma AB is a clinical-stage biotech company focused on resolving inflammation through selective activation of the melanocortin system. The company has a platform technology based on a new class of drug candidates that target acute exacerbations in chronic inflammatory diseases with the primary aim of stimulating natural healing mechanisms. AP1189, the company's lead drug candidate, is being evaluated in three Phase 2 clinical programs regarding rheumatoid arthritis, idiopathic membranous glomerulonephritis and virus-induced respiratory failure.

SynAct Pharma AB (OSTO:SYNACT) Headlines

No Headlines